How DADA Works
DADA
PDK4 and Cellular Energy: A Research Mechanism Overview
PDK4 inhibition is an emerging area of metabolic research. This page walks through the proposed mechanism behind that interest — distinguishing laboratory findings from what they do or don’t tell us about the MacDaddy product. No dosing or self-use instructions are provided.
What is DADA?
DADA stands for diisopropylamine dichloroacetate. It is a small-molecule salt, not a peptide. Research on DADA should not be treated as interchangeable with research on sodium dichloroacetate (DCA).
DADA has been investigated in liver disease as well as cellular energy metabolism. Its medicinal history and human liver research provide a different perspective from the PDK4 mechanism studies discussed below.
DADA’s Medicinal History in Japan
DADA has been marketed in Japan as Liverall for chronic liver disease. In their 2014 paper, Yamane and colleagues described more than 50 years of Japanese use at that time. Read the published account of its medicinal history.
The Japanese indication is improvement of liver function in chronic liver disease. Liverall’s patient information also describes an action that helps suppress fatty-liver formation. This is a broader indication than a specific claim to cure fatty liver disease. Japanese Liverall patient information.
Human Research: Nonalcoholic Fatty Liver Disease
Lu and colleagues (2005) conducted a multicentre, randomised, double-blind study involving 127 patients with nonalcoholic fatty liver disease. Over eight weeks, the study compared two oral DADA dose groups.
The authors reported improvements in clinical symptoms, liver enzyme ALT measurements and blood lipids. ALT is a blood marker used to assess liver injury; an improvement in this marker does not by itself establish reversal of liver scarring.
How to interpret the findings: Both groups received DADA, so the study compared doses rather than DADA against placebo. Its short duration limits conclusions about lasting benefit and long-term safety. This research concerns the medicinal preparations studied and does not establish equivalent effects from the MacDaddy research product.
Conceptual Graphic: Cellular Energy Pathways
How to read the supplied graphic: It illustrates the concepts of energy support, mitochondrial integrity and signalling discussed in this mechanism model. Glycolysis occurs in the cytosol, outside the mitochondrion. Pyruvate must be converted to acetyl-CoA before entering the TCA cycle. Fatty acids and amino acids feed metabolism through other entry points; they do not all follow glucose through glycolysis.
1. Glucose metabolism
Cells break glucose down into pyruvate through glycolysis. This produces some ATP and supplies carbon for subsequent reactions.
2. The mitochondrial gateway
The pyruvate dehydrogenase complex (PDH) converts pyruvate into acetyl-CoA. PDK enzymes can reduce PDH activity by adding phosphate groups.
3. Downstream energy
Acetyl-CoA feeds the TCA cycle. Electron carriers then supply the respiratory chain, helping drive ATP synthesis. Oxygen, fuel supply and cellular demand all influence the outcome.
The Proposed Mechanism: Easing a Metabolic Brake
Think of PDK4 as one brake on PDH. In a 2014 study, researchers reported DADA inhibition of recombinant PDK4 and restoration of reduced PDH activity and tissue ATP in influenza-infected mice. This was a specific disease model, not a study of energy enhancement in healthy people. Read the original study.
When the brake is engaged
- PDK-mediated phosphorylation reduces PDH activity.
- Less pyruvate can pass through this gateway under otherwise comparable conditions.
- Glucose-derived mitochondrial oxidation may fall.
If DADA reduces that brake
- PDK4 inhibition could favour more active PDH.
- More pyruvate could be converted to acetyl-CoA.
- Downstream oxidation and ATP availability could change, depending on the model.
This is a simplified model of the proposed pathway, offered as a starting point for understanding how PDK4 inhibition is hypothesized to work.
What Researchers Would Need to Measure
Target activity
Does the compound affect the intended enzyme at the exposure being studied?
Metabolic changes
Do measured changes in glucose oxidation, lactate and ATP agree with the proposed mechanism?
Safety and translation
Are effects reproducible, and do they translate across tissues and species without harmful effects?
Research Context
The cited 2014 study is a specific disease-model finding (influenza-infected mice), which makes it a promising lead for further research rather than a settled picture of energy, athletic performance or broader cellular benefits in people. A change in ATP within that experimental system is a distinct, measured data point — not the same claim as a person feeling more energetic. As with any research compound, the MacDaddy product’s own safety and effectiveness profile would need to be established separately.
Primary Research
Yamane and colleagues (2014), PLOS ONE: Diisopropylamine Dichloroacetate, a Novel Pyruvate Dehydrogenase Kinase 4 Inhibitor, as a Potential Therapeutic Agent for Metabolic Disorders and Multiorgan Failure in Severe Influenza.